Vikram Solar Q2FY27: consolidated PAT crashes 95% YoY to ₹5.9 Cr as margins compress
PAT -95.38% YoY · revenue -2.93% · margins compressing · miss vs street
₹1,077.42 Cr
-2.93% YoY
₹5.93 Cr
-95.38% YoY
0.54%
-10.9pp YoY
₹0.16
Vikram Solar's consolidated PAT for Q2FY27 (quarter ended September 30, 2026) collapsed 95.4% year-on-year to ₹5.9 Cr, down from ₹128.5 Cr in Q2FY26, even as consolidated revenue held roughly flat at ₹1,077.4 Cr (-2.9% YoY). The decline is also sequential: PAT fell 70% from Q1FY27's already-weak ₹19.8 Cr, while revenue dropped 31% from ₹1,563.1 Cr, undercutting Prabhudas Lilladher's pre-quarter estimate of roughly +35.6% YoY revenue growth (October 7, 2026 sector preview) by a wide margin — a clear miss against Street's growth expectation, not just a margin story.
Q2 FY-2027 vs prior quarters
The margin bridge explains most of the damage: consolidated operating margin (EBITDA/revenue) fell to 9.4% from 21.2% a year ago, even though it edged up from Q1's 8.1%, and net margin shrank to 0.5% from 11.4% YoY. Finance costs rose 35% YoY to ₹42.7 Cr and depreciation jumped 89% YoY to ₹65.8 Cr as the 9 GW TOPCon cell-plant capex lands on the balance sheet — consolidated borrowings have risen more than 6x since March 2026 to ₹631.8 Cr, and H1FY27 capex on property, plant and CWIP reached ₹981.6 Cr, consistent with management's cited ₹5,000 Cr FY27-28 capex plan. No exceptional items appear in either the standalone or consolidated statement this quarter, so the swing is operating, not a one-off.
The stock went into the print at ₹143.85, down 2% over the past month of trading.
What the summary numbers don't show
EPS (basic) ₹0.16 for the quarter vs ₹3.83 a year ago and ₹0.55 in Q1FY27.
FY27 EBITDA target of ₹1,500-1,600 Cr not reaffirmed; management deferred full-year guidance pending H1 clarity on DCR pricing, distribution penetration, and ALMM 2 policy finalization. Cell plant commissioning Q4 FY27 on track; 40-50% utilization targeted for FY28. Capex ~₹5,000 Cr in FY27-28.
— This quarter: missed
Management did not reaffirm the FY27 EBITDA target of ₹1,500-1,600 Cr flagged at the Q1 call; H1FY27 consolidated EBITDA of roughly ₹227 Cr tracks far below the run-rate that target implies, and no formal FY27 guidance is on record — consistent with the prior call's cautious tone and the deferral pending clarity on DCR pricing, distribution penetration and ALMM 2 policy. The one concrete positive on record is the 9 GW TOPCon cell plant, reported on track for December 2026 commissioning (October 23 project update), which management has tied to 40-50% utilisation in FY28. The quarter's order wins — a 289.87 MWp module order from NLC India (Oct 27) and a 187 MW supply order (Oct 15) — add to the book but aren't large enough to move this quarter's print. No management press release accompanied this filing, so there is no company commentary to reconcile against the numbers beyond the notes to the financial statements.
W1
9 GW TOPCon cell plant commissioning — on track for Dec 2026; ramp to management's targeted 40-50% utilisation in FY28 is the next margin lever to verify.
W2
FY27 EBITDA guidance (previously ₹1,500-1,600 Cr) remains undisclosed — watch for reinstatement once DCR pricing, distribution penetration and ALMM 2 policy finalise.
W3
Finance cost and depreciation trajectory as the ~₹5,000 Cr FY27-28 capex plan continues; H1FY27 capex already ₹981.6 Cr (consolidated).
Figures converted from ₹ million (source) to ₹ Cr; no exceptional items in either statement this quarter; ₹148.5 Cr safeguard-duty receivable (sub judice) and ₹52.8 Cr withheld trade receivables are balance-sheet contingencies per Notes 6-7, not P&L items; EPS not annualised for the quarter.
Margin recovery the focus as TOPCon ramp hits stride
After Q1's brutal 85% PAT collapse despite 38% revenue growth, Q2 FY27 is a litmus test for whether the new TOPCon plant is normalizing or headwinds persist. The 9 GW cell plant coming online in December could be the rerating catalyst.
The setup: margin trajectory is everything
Q1 FY27 delivered a textbook bull-trap print: revenue surged 38% YoY to ₹1,563 Cr on the back of the new module plant commissioned in July 2026, but net profit collapsed 85% to just ₹19.8 Cr. The stock has paid the price, down 66% from its all-time high. The market's question for Q2 is simple: was that profit crater a one-time commissioning hit, or is the new TOPCon capacity fundamentally margin-dilutive? The answer will drive sentiment into the critical December quarter, when the 9 GW cell plant begins first production.
~₹1,500–1,600 Cr
On-plan from Q1 run-rate; 11+ GW order book supports volumes
Stabilization key
Q1 ₹19.8 Cr was crash; Q2 FY26 was ₹128 Cr. Margin recovery would signal ramp is normalizing
FY27 guidance 1.7x FY26
CFO said per-unit outcome expected to match Q2/Q4 FY26; suggests ramp headwinds near-term
What a strong quarter looks like: Revenue tracking Q1 (₹1,500+ Cr), PAT stabilizing to double-digit ₹20–30+ Cr range (signal that commissioning costs are normalizing), management reaffirming the 9 GW cell plant timeline for December production, and order book commentary staying upbeat (more wins in the pipeline). What a weak quarter looks like: Revenue dipping below Q1, PAT staying crushed at single-digit Cr (signal that margin pressure is structural, not transient), any pushback on cell plant timeline, or guidance walk-backs on FY27 EBITDA.
On track for full-year?
Management guided FY27 EBITDA to be 1.7x FY26 in absolute terms, with per-unit economics expected to match Q2 and Q4 of FY26 (the pre-TOPCon, pre-margin-pressure period). The fact that Q1 delivered ₹1,563 Cr in revenue but only ₹19.8 Cr in profit suggests the company is in heavy investment/ramp mode. If Q2 shows profit stabilization—even if still below Q2 FY26's ₹128 Cr—it would suggest management's guidance is on track. A deeper profit dip would raise questions about execution risk or market oversupply.
What the Street says
Recent filings & corporate activity
1 · Order wins accelerating
October 2026 saw a 289.87 MWp supply order from NLC India for TOPCon modules (Oct 27). September saw a 400 MW agri-solar module order (Sep 28) and a 124 MW supply contract for Andhra Pradesh (Sep 11). These signal solid downstream demand despite the stock's weakness, and underscore the company's pivot to higher-margin TOPCon product.
2 · Cell plant ramp (Dec target unshaken)
Management reaffirmed on October 23 that the 9 GW N-type TOPCon cell plant at Gangaikondan is on schedule to produce its first cells in December 2026. This is a key inflection point: own cell supply could improve margins and reduce outside cell-procurement costs as volumes scale.
3 · Senior sales executive departure
EVP Sales & BD Rony Banerjee resigned on September 29, with a Chief Business Officer appointed. A management shuffle at the sales head during a ramp suggests either internal restructuring or execution pressure—worth monitoring for commentary on the call.
4 · Ownership and insider activity
No recent promoter pledges or insider selling. Promoter holding stable at 63%. FII increased 43 bps QoQ to 3.37% (suggesting some tactical interest), while DII dipped 77 bps to 4.03%. Bulk deals in August 2026 were inter-dealer trades with no insider red flags.
Numbers to watch on results day
Revenue
~₹1,500–1,600 Cr
Volume trajectory; should track Q1 if order book flows
₹1,563 Cr
Net profit
₹30–50 Cr (est.)
Margin stabilization is THE swing factor; below ₹20 Cr = missed guidance risk
₹19.8 Cr (−85% YoY)
EBITDA
Track FY27 1.7x guidance
Should show positive EBITDA trajectory if on-plan
Not disclosed
Order book
Track new wins
11+ GW post-July orders; confirm if momentum sustains
Not specified Q1
Vikram Solar is at an inflection: the ₹1,563 Cr Q1 revenue print proved demand is there, but the 85% PAT collapse raised the bar for Q2 to show meaningful margin recovery. The 9 GW cell plant—first production in December—is the bigger story; own-supply economics could re-rate the stock if execution stays on track. Management's FY27 EBITDA guidance (1.7x FY26) suggests conviction in the ramp, but investors want to see profit turning a corner, not just top-line growth.
Three things to listen for on the call: (1) Is the Q1 margin squeeze a commissioning effect or a market headwind? (2) December cell plant timeline—any slippage or cost changes? (3) What's the path to ₹128 Cr+ PAT levels seen in prior mature quarters? A solid profit print and a clean cell-plant commentary could pivot sentiment; a disappointing PAT would deepen the discount.